Major 7-Year trial seeks best MS treatment for kids

NCT ID NCT04926818

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aims to find out if two newer MS medications (ofatumumab and siponimod) work as well as or better than an existing one (fingolimod) in controlling relapses for children and teens aged 10-17. It will follow about 120 young patients for up to 7 years to compare how often they have MS attacks and monitor safety. The goal is to identify the most effective and safest long-term treatment option for pediatric MS.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arkansas Childrens Hosp Rsch Inst

Little Rock, Arkansas, 72202, United States
Axiom Clinical Research of Florida

Tampa, Florida, 33609, United States
Childrens Hospital Los Angeles

Los Angeles, California, 90027, United States
Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104 4399, United States
Childrens National Medical Center

Washington D.C., District of Columbia, 20010, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Novartis Investigative Site

CABA, C1181ACH, Argentina
Novartis Investigative Site

Parkville, Victoria, 3052, Australia
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Esneux, 4130, Belgium
Novartis Investigative Site

Ghent, 9000, Belgium
Novartis Investigative Site

Curitiba, Paraná, 81210-310, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90430-001, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 05403-000, Brazil
Novartis Investigative Site

Montreal, Quebec, H3A 2B4, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1C5, Canada
Novartis Investigative Site

Lo Barnechea, Santiago Metropolitan, 7691236, Chile
Novartis Investigative Site

Zagreb, 10000, Croatia
Novartis Investigative Site

Tallinn, 11315, Estonia
Novartis Investigative Site

Le Kremlin-Bicêtre, 94275, France
Novartis Investigative Site

Montpellier, 34090, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Göttingen, Lower Saxony, 37075, Germany
Novartis Investigative Site

Bochum, 44791, Germany
Novartis Investigative Site

Guatemala City, 01015, Guatemala
Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, 110017, India
Novartis Investigative Site

Lucknow, Uttar Pradesh, 226014, India
Novartis Investigative Site

Kolkata, West Bengal, 700017, India
Novartis Investigative Site

Petah Tikva, 4920235, Israel
Novartis Investigative Site

Roma, RM, 00165, Italy
Novartis Investigative Site

Naples, 80131, Italy
Novartis Investigative Site

Riga, LV-1004, Latvia
Novartis Investigative Site

Mexico City, Mexico City, 06700, Mexico
Novartis Investigative Site

Mexico City, Mexico City, 06720, Mexico
Novartis Investigative Site

Gdansk, 80-214, Poland
Novartis Investigative Site

Lodz, 93-338, Poland
Novartis Investigative Site

Poznan, 60-355, Poland
Novartis Investigative Site

Warsaw, 04-730, Poland
Novartis Investigative Site

Coimbra, 3000-602, Portugal
Novartis Investigative Site

Lisbon, 1169-050, Portugal
Novartis Investigative Site

Belgrade, 11000, Serbia
Novartis Investigative Site

Bratislava, 833 40, Slovakia
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Seville, 41009, Spain
Novartis Investigative Site

Tainan, 704302, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Izmir, Karsiyaka, 35575, Turkey (Türkiye)
Novartis Investigative Site

Kocaeli, 41380, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS (MS)